Tech Company Financing Transactions
Innate Pharma Funding Round
Innate Pharma closed a $16.4 million funding round on 4/24/2025. Investors included Sanofi Ventures.
Transaction Overview
Company Name
Announced On
4/24/2025
Transaction Type
Venture Equity
Amount
$16,350,000
Round
Undisclosed
Investors
Sanofi Ventures (Lead Investor)
Proceeds Purpose
The proceeds from this capital increase will be used for general corporate purposes, including extending our cash runway to support continued pipeline execution and long-term value creation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
117, Avenue de Luminy - BP 30191
Marseille, 13009
FR
Marseille, 13009
FR
Phone
Website
Email Address
Overview
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and ALab picturentibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Dickinson
Chief Financial Officer
Frédéric Lombard
Chief Operating Officer
Yannis Morel
Browse more venture capital transactions:
Prev: 4/24/2025: ChEmpower venture capital transaction
Next: 4/24/2025: MagicBlock venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs